Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disor...
Q1 2026
May 12, 2026
FY 2025
Mar 12, 2026
Q4 2025
Q3 2025
Nov 12, 2025
Q2 2025
Aug 13, 2025